Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)
Phase 3
Completed
- Conditions
- AtherosclerosisHypercholesterolemia
- Interventions
- Drug: EzetimibeDrug: Placebo
- First Posted Date
- 2008-04-02
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 137
- Registration Number
- NCT00651404
An Open-label, Single Center Trial to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Org 36286 (P07004)
Phase 1
Completed
- Conditions
- Infertility
- Interventions
- Drug: Org 36286Drug: Lyndiol®
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 24
- Registration Number
- NCT00647933
4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 56
- Registration Number
- NCT00641771
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 46
- Registration Number
- NCT00636207
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
Phase 2
Completed
- Conditions
- Airway InflammationAsthma
- Interventions
- Drug: mometasone furoate/formoterol 200/10 mcgDrug: mometasone furoate/formoterol 100/10 mcgDrug: MF MDI 200 mcgDrug: MF DPI 200 mcgDrug: PlaceboDrug: mometasone furoate/formoterol 400/10 mcg
- First Posted Date
- 2008-03-14
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 93
- Registration Number
- NCT00635882
A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Implanon (etonogestrel implant)Drug: Radiopaque Implanon
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 108
- Registration Number
- NCT00620464
A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702)
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 301
- Registration Number
- NCT00620035
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 31
- Registration Number
- NCT00604812
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
Phase 3
Completed
- Conditions
- COPDAsthma
- Interventions
- Drug: SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 272
- Registration Number
- NCT00604500
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
Phase 3
Completed
- Conditions
- Allergic RhinitisAsthma
- Interventions
- Drug: Mometasone furoate nasal spray (MFNS)Drug: Placebo nasal spray
- First Posted Date
- 2008-01-23
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 51
- Registration Number
- NCT00599027
© Copyright 2025. All Rights Reserved by MedPath